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Abstract
Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), remains a serious global health concern. Since their
emergence in the mid-1970s multi-drug resistant (MDR) S. Typhi now dominate drug sensitive equivalents in many regions.
MDR in S. Typhi is almost exclusively conferred by self-transmissible IncHI1 plasmids carrying a suite of antimicrobial
resistance genes. We identified over 300 single nucleotide polymorphisms (SNPs) within conserved regions of the IncHI1
plasmid, and genotyped both plasmid and chromosomal SNPs in over 450 S. Typhi dating back to 1958. Prior to 1995, a
variety of IncHI1 plasmid types were detected in distinct S. Typhi haplotypes. Highly similar plasmids were detected in co-
circulating S. Typhi haplotypes, indicative of plasmid transfer. In contrast, from 1995 onwards, 98% of MDR S. Typhi were
plasmid sequence type 6 (PST6) and S. Typhi haplotype H58, indicating recent global spread of a dominant MDR clone. To
investigate whether PST6 conferred a selective advantage compared to other IncHI1 plasmids, we used a phenotyping array
to compare the impact of IncHI1 PST6 and PST1 plasmids in a common S. Typhi host. The PST6 plasmid conferred the ability
to grow in high salt medium (4.7% NaCl), which we demonstrate is due to the presence in PST6 of the Tn6062 transposon
encoding BetU.
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Introduction
Typhoid fever remains a serious public health problem in many
developing countries, with highest incidence in parts of Asia (274
per 100,000 person-years) and Africa (50 per 100,000 person-
years) [1,2]. The causative agent is the bacterium Salmonella enterica
serovar Typhi (S. Typhi). While vaccines against S. Typhi exist, it
is mainly restricted groups such as travellers [3,4] and individuals
enrolled in large vaccine trials [5] who are immunized, and
antimicrobial treatment remains central to the control of typhoid
fever [3]. However antimicrobial resistant typhoid has been
observed for over half a century and is now common in many
areas. Chloramphenicol resistant S. Typhi was first reported in
1950, shortly after the drug was introduced for treatment of
typhoid [6]. By the early 1970s, S. Typhi resistant to both
chloramphenicol and ampicillin had been observed [7] and
multidrug resistant (MDR) S. Typhi (defined here as resistance
to chloramphenicol, ampicillin and trimethoprim-sulfamethoxa-
zole) emerged soon after [8]. The rate of MDR among S. Typhi
can fluctuate over time and geographical space, as can the precise
combination of drug resistance genes and phenotypes [9,10].
However in many typhoid endemic areas, an increasing
prevalence of MDR S. Typhi was observed in the late 1990s
[11,12,13], and MDR typhoid now predominates in many areas
[9,14] including parts of Asia [15,16], Africa [17] and the Middle
East [18,19,20,21]. MDR S. Typhi with reduced susceptibility to
fluoroquinolones are increasingly common [9,15,16,22], leaving
macrolides or third generation cephalosporins as the only options
for therapy [23,24].
In S. Typhi the MDR phenotype is almost exclusively conferred
by self-transmissible plasmids of the HI1 incompatibility type
(IncHI1) [8,11,25,26,27,28,29,30], although other plasmids are
occasionally reported [31]. In the laboratory, IncHI1 plasmids can
transfer between Enterobacteriaceae and other Gram-negative
bacteria [32] and in nature, IncHI1 plasmids have been detected
in pathogenic isolates of Salmonella enterica and Escherichia coli
[33,34,35,36]. However it remains unclear whether the increase in
MDR typhoid is due to the exchange of resistance genes among
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co-circulating S. Typhi or to the expansion of MDR S. Typhi
clones. Efforts have been made to investigate variability within
IncHI1 plasmids [29,33,37] or their S. Typhi hosts [22,38,39,
40,41] but little progress has been made in linking the two together
to answer fundamental questions of how MDR typhoid spreads.
We recently developed a plasmid multi-locus sequence typing
(PMLST) scheme for IncHI1 plasmids, which identified eight
distinct IncHI1 plasmid sequence types (PSTs) among S. Typhi
and S. Paratyphi A isolates, including five PSTs found in S. Typhi
[37]. This pattern was not consistent with a single acquisition of an
IncHI1 plasmid in S. Typhi followed by divergence into multiple
plasmid lineages, rather it indicated that divergent IncHI1
plasmids have entered the S. Typhi population on multiple
occasions [37]. However the phylogenetic relatedness of the S.
Typhi hosts was not determined, thus we were unable to estimate
how many times plasmids may have been independently acquired.
In this study, we aimed to investigate the relative contribution of
plasmid transfer, as opposed to the expansion of plasmid-bearing
S. Typhi clones, to the emergence of MDR typhoid. We found
evidence for plasmid transfer in older S. Typhi. However the vast
majority of recent MDR typhoid was attributable to a single host-
plasmid combination (S. Typhi H58-IncHI1 plasmid ST6). We
performed further experiments to investigate possible mechanisms
for the success of this host-plasmid combination, and identified a
transposon in PST6 that confers tolerance to high osmolarity.
Materials and Methods
Bacterial isolates and DNA extraction
The bacterial isolates analyzed by SNP assay are summarized in
Table 1 and listed in full in Table S1. DNA was extracted using
Wizard Genomic DNA purification kits (Promega) according to
manufacturer’s instructions. Details of the isolates used for
competition experiments are also listed in Table S1.
BRD948 is an attenuated Ty2-derived strain (also known as
CVD908-htrA), which has deletion mutations in aroC (t0480), aroD
(t1231), and htrA (t0210) [42]. The growth of BRD948 on LB agar
or in LB broth was enabled by supplementation with aromatic
amino acid mix (aro mix) to achieve the final concentration of
50 mM L-phenylalanine, 50 mM L-tryptophan, 1 mM para-ami-
nobenzoic acid and 1 mM 2,3-dihydroxybenzoic acid.
Identification and phylogenetic analysis of IncHI1 SNPs
Plasmid sequences were downloaded from the European
Nucleotide Archive (plasmid details and accessions in Table 2).
SNPs between finished plasmid sequences were identified using the
nucmer and show-snps algorithms within the MUMmer 3.1 package
[43], via pairwise comparisons with pAKU_1. To identify SNPs in
S. Typhi PST6 IncHI1 plasmids, 36 bp single-ended Illumina/
Solexa sequencing reads from S. Typhi isolates E03-9804, ISP-03-
07467 and ISP-04-06979 were aligned to the pAKU_1 sequence
using Maq [44] and quality filters as described previously [45].
SNPs called in repetitive regions or inserted sequences were
excluded from phylogenetic analysis, so that phylogenetic trees
were based only on the conserved IncHI1 core regions. This
resulted in a total of 347 SNPs, which were analyzed using BEAST
[46] to simultaneously infer a phylogenetic tree and divergence
dates (using the year of isolation of each plasmid as listed in
Table 1, resulting tree in Figure 1). Parameters used were as
follows: generalised time reversible model with a Gamma model of
site heterogeneity (4 gamma categories); a relaxed molecular clock
with uncorrelated exponential rates [46], a coalescent tree prior
estimated using a Bayesian skyline model with 10 groups [47],
default priors and 20 million iterations.
SNP typing analysis
The chromosomal haplotype of S. Typhi isolates was deter-
mined based on the SNPs present at 1,485 chromosomal loci
identified previously from genome-wide surveys [41,45] and listed
in [22,39]. IncHI1 plasmid haplotypes were determined using 231
SNPs located in the conserved IncHI1 backbone sequence, listed
in Table S2 (note these do not include SNPs specific to pMAK1 or
pO111_1 which were not available at the time of assay design, nor
any SNPs falling within 10 bp of each other as these cannot be
accurately targeted via GoldenGate assay; however additional
SNPs identified via plasmid MLST [37] were included, see Table
S2). Resistance gene sequences were interrogated using additional
oligonucleotide probes, listed in [16]. All loci were interrogated
using a GoldenGate (Illumina) custom assay according to the
manufacturer’s standard protocols, as described previously [16,
22,39]. SNP calls were generated from raw fluorescence signal
data by clustering with a modified version of Illuminus [48] as
described previously [22]. The percentage of IncHI1 SNP loci
yielding positive signals in the GoldenGate assay clearly divided
isolates into two groups, indicating presence of an IncHI plasmid
(signals for .90% of IncHI1 loci) or absence of such a plasmid
(signals for ,10% of IncHI1 loci), see Figure 2. SNP alleles were
concatenated to generate two multiple alignments, one for
chromosomal SNPs and one for IncHI1 plasmid SNPs. Maximum
likelihood phylogenetic trees (Figure 3) were fit to each alignment
using RAxML [49] with a GTR+C model and 1,000 bootstraps.
PCR
PCR primers were designed using Primer3 [50] according to
the following criteria: melting temperature 56uC, no hairpins or
dimers affecting 39 ends, no cross-dimers between forward and
reverse primers. Primer sequences are given in Table 3. PCRs
were performed on a TETRA DNA Engine Peltier Thermal
Cycler (MJ Research) with a reaction consisting of 1.2 ml of 10X
Mango PCR buffer, 1.5 mM MgCl2, 25 mM of each dNTP,
1.25 U Mango Taq (Bioline), 0.3 mM of each primer, 1.0 ml DNA
template (approx. 100 ng) and nuclease free water in a total
Author Summary
Typhoid fever is caused by the bacterium Salmonella
enterica serovar Typhi (S. Typhi). Treatment relies on
antimicrobial drugs, however many S. Typhi are multi-drug
resistant (MDR), severely compromising treatment options.
MDR typhoid is associated with multiple drug resistance
genes, which can be transferred between S. Typhi and
other bacteria via self-transmissible plasmids. We used
sequence analysis to identify single nucleotide polymor-
phisms (SNPs) within these plasmids, and used high-
resolution SNP typing to trace the subtypes (termed
haplotypes) of both the S. Typhi bacteria and their MDR
plasmids isolated from more than 450 typhoid patients
since 1958. Among isolates collected before 1995, a variety
of plasmid haplotypes and S. Typhi haplotypes were
detected, indicating that MDR typhoid was caused by a
diverse range of S. Typhi and MDR plasmids. In contrast,
98% of MDR S. Typhi samples isolated from 1995 were of
the same S. Typhi haplotype and plasmid haplotype,
indicating that the recent increase in rates of MDR typhoid
is due to the global spread of a dominant S. Typhi-plasmid
combination. We demonstrate this particular plasmid type
contains a transposon encoding two transporter genes,
enabling its S. Typhi host to grow in the presence of high
salt concentrations.
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reaction volume of 12 ml. Cycling conditions were as follows:
5 min at 94uC, 30 cycles of 15 s at 94uC, 15 s at 58uC, and 60 s at
72uC; final extension of 5 min at 72uC.
Plasmid transfer
The transfer of pHCM1 and pSTY7 from respective E. coli
transconjugants to the attenuated S. Typhi BRD948 was
performed by cross-streaking onto LB agar supplemented with
aro mix and incubating at 37uC overnight. The growth was
harvested, resuspended in 2 ml of dH20, plated on MacConkey
agar containing streptomycin (1 mg/ml or 5 mg/ml) and chloram-
phenicol (5 mg/ml or 20 mg/ml) and incubated overnight at 37uC.
BRD948 transconjugants were confirmed by antimicrobial suscep-
tibility patterns (disk diffusion) and colony PCR specific for
BRD948 background (primers 5939-59-CGTTCACCTGGCT-
GGAGTTTG-39 and5940-59-CATGCCAGCAGCGCAATCG-
CG-39) and pHCM1 or pSTY7 plasmids (Insert1056L- 59-TA-
GGGTTTGTGCGGCTTC-39 and Insert1056R-59-CCTTCTT-
GTCGCCTTTGC-39).
Competition assays in common host background
The competition between BRD948 (pHCM1) and BRD948
(pSTY7) was started with equal inoculums of roughly 56103 cfu
each in 10 mL of LB broth supplemented with aro mix and
chloramphenicol (5 mg/mL). The culture was incubated for
16 hours at 37uC with shaking. Approximately 104 cfu of this
culture were then used to inoculate the next passage. The cultures
were passaged for a total of 4 days. Samples were collected at time
point 0 (at the time of initial inoculation) and after 1, 2, 3 and 4
days of passage, diluted and spread on LB agar supplemented with
aro mix. Sixty-four colonies from each sample were randomly
picked and tested by PCR to identify their plasmid type (see
below). The entire competition assay was performed in triplicate,
i.e. beginning with three initial cultures of equal inoculums of the
two isolates. The colony PCR was perform using standard con-
dition (see PCR section above) with three primers (DF 59-
CGATTTGTGAAGTTGGGTCA-39, DR2 59- CAACCTGGG-
CAGGTGTAAGT-39 and DR3 59- TTCGTTACGTGTTCAT-
TCCA-39). Expected sizes of PCR products were 511 bp for
BRD948 (pHCM1) and 285 bp for BRD948 (pSTY7).
Competition assays using wildtype isolates
Four individual competitive growth assays were performed using
wildtype host-plasmid combinations genotyped using the Gold-
enGate assay (isolates listed in Table S1); H58-C vs. H1, H58-E1 vs.
H1, H58-C-ST6 vs. H1-ST1 and H58-E1-ST6 vs. H1-ST1.
Bacterial isolates were recovered from frozen stocks onto Luria-
Bertani (LB) media, supplemented with 20 mg/ml of chloram-
phenicol for isolates with MDR plasmids. Individual colonies were
picked and used to inoculate 10 ml of LB broth, which were
incubated overnight at 37uC with agitation. Bacterial cells were
enumerated the following day by serial dilution and plating.
Equivalent quantities of the two competing S. Typhi isolates were
inoculated into 10 ml of LB broth and were incubated as before
(Day 0). The competition assays were conducted by growing the
mixed bacteria to stationary phase and then passaging them into
Table 1. Summary of 454 S. Typhi isolates analyzed in this study.
Region No. countries pre-1970s 1970s–1980s 1990s 2000–2007 Total isolates
South & Central America 4 0 6 3 2 11
Central, Southern, East Africa 7 10 3 3 26 42
North Africa 3 11 1 8 5 25
West Africa 11 28 0 6 12 46
East Asia 8 5 8 22 187 222
Indian Subcontinent 3 0 3 1 66 70
Middle East 3 0 0 0 31 31
Europe 5 1 1 2 2 6
Unknown - 1 0 0 0 1
Total 44 56 22 45 331 454
doi:10.1371/journal.pntd.0001245.t001
Table 2. IncHI1 plasmid sequences analyzed in this study.
Plasmid Host Year of isolation Plasmid type Accession Citation
pHCM1 S. Typhi strain CT18 1993 PST1 AL513383 [54]
pAKU_1 S. Paratyphi A strain AKU_12601 2003 PST7 AM412236 [33]
R27 S. Typhimurium 1961 PST5 AF250878 [65]
pMAK1 S. Choleraesuis strain L-2454 2002 PST1 AB366440 -
pO111_1 E. coli O111:H- strain 11128 2001 PST1 AP010961 [66]
p9804_1 S. Typhi strain E03-9804 2004 PST6 ERA000001 [45]
p7467_1 S. Typhi strain ISP-03-07467 2003 PST6 ERA000001 [45]
p6979_1 S. Typhi strain ISP-04-06979 2004 PST6 ERA000001 [45]
doi:10.1371/journal.pntd.0001245.t002
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10 ml of LB broth in a 1:1000 dilution in triplicate over four days.
Oneml of media containing bacteria from each of the triplicates was
stored at 280uC at each time point. DNA was extracted from the
frozen samples by boiling for 10 minutes, samples were pelleted, the
supernatant was removed and used as template in all of the
subsequent competitive real-time PCR reactions (below), which
were performed on each template in duplicate.
Real-time PCR for quantitation of wildtype isolates in
competition assays
We performed two individual competitive real-time PCRs
(Taqman system) with LNA probes to calculate the proportions of
S. Typhi H1 vs. S. Typhi H58 and S. Typhi H58-C vs. S. Typhi
H58-E1 in aliquots of DNA extracted from broth following
competitive growth. These assays were performed to accurately
Figure 2. Distribution of IncHI1 loci among S. Typhi isolates. X-axis indicates the number of IncHI1 plasmid loci (out of 231 targets) generating a
fluorescent signal in the Illumina GoldenGate SNP assay. Isolates clearly fall into two groups: either.90% of IncHI1 target loci were detected, taken to
imply presence of an IncHI1 plasmid (red), or ,10% of IncHI1 target loci were detected, taken to imply absence of any IncHI1 plasmid (blue).
doi:10.1371/journal.pntd.0001245.g002
Figure 1. Phylogenetic tree for IncHI1 plasmid sequences. Phylogenetic tree based on 347 SNPs identified among 8 publicly available IncHI1
plasmid sequences (Table 2), constructed using BEAST (with 20 million iterations, 4 replicate runs, exponential clock model). Terminal nodes are labelled
with the organism of origin (STy = Salmonella enterica serovar Typhi, SCh = Salmonella enterica serovar Choleraesuis, STm = Salmonella enterica
serovar Typhimurium, SPa = Salmonella enterica serovar Paratyphi A, Ec = E. coli O111:H-) and date of isolation. Isolation dates were input into the
BEAST model in order to estimate divergence dates for internal nodes (open circles, labelled with divergence date estimates; brackets indicate 95%
highest posterior density interval). Insertion sites (grey) are based on sequence data and verified (except for pO111_1 and pMAK1) by PCR. Precise
insertion sites and PCR primers for verification are given in Tables 3 & 4. Four major plasmid groups, PST1, PST5, PST6, PST7, are coloured as labelled.
doi:10.1371/journal.pntd.0001245.g001
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Figure 3. Phylogenetic trees of S. Typhi chromosome and IncHI1 plasmid. (A) Phylogenetic tree indicating chromosomal haplotypes of 454
S. Typhi isolates determined by SNP typing with the GoldenGate assay. Circles correspond to detected S. Typhi haplotypes; node sizes are scaled to
the number of isolates detected with that haplotype and labelled with this number. Unfilled circle indicates tree root; reference isolates used to
define the S. Typhi SNPs are labelled with the isolate name. S. Typhi haplotypes in which IncHI1 plasmids were detected (N= 201) are coloured; black
circles indicate no IncHI1 plasmids were found among S. Typhi of that haplotype; other colours indicate the presence of specific IncHI1 plasmid
haplotypes corresponding to the colours in (B). Note that most of the coloured nodes also contain S. Typhi isolates with no plasmid, and the colours
do not represent the proportion of isolates harbouring the various plasmid types. (B) Phylogenetic tree of IncHI1 plasmids determined by SNP typing
with the GoldenGate assay (coloured leaf nodes); grey leaf nodes indicate the position of non-S. Typhi plasmids, as determined from plasmid
sequence data listed in Table 2.
doi:10.1371/journal.pntd.0001245.g003
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calculate the relative proportion of the isolates in all competitive
assays, including those that could not be calculated by plating alone.
The haplotype specific primers and probes were designed using
Primer Express Software (Applied Biosystems) and manufactured
by Sigma-Proligo (Singapore). Primer and probe sequences were as
follows (capital letters indicate the position of LNA and the letters in
square brackets indicate the SNP position); H58 vs H1 (99 bp
amplicon): F(71–83)-CCGAACGCGACGG, R(169-157)-TGCG-
GCACACGGC and probe 59-FAM-ccggtAat[G]gtAatGaagc-
BHQ1 (S. Typhi H1) and 59-Hex-ccggtAat[A]gtAatGaagc (S.
Typhi H58); H58-C vs H58-E1 (89 bp amplicon): F(60–75)-
ACCCTGCACCGTGACC, R-(148–135)-GCATGATGCCGC-
CC and probe 59-FAM-ttcCag[G]ccAtgAcgc –BHQ1 (S. Typhi
H58-C) and 59-HEX-ttcCag[A]ccAtgAcgc-BHQ1 (S. Typhi H58-
E1). PCR amplification were performed using a light cycler (Roche,
USA), with hot start Taq polymerase (Qiagen, USA) under the
following conditions, 95uC for 15 minutes and 45 cycles of 95uC for
30 seconds, 60uC for 30 seconds and 72uC for 30 seconds. As the
primer locations were identical for the internal competitive PCR
assay, the efficiency of the PCR was also considered to be identical.
Therefore, proportions of isolates at the various time points
throughout the assay were calculated by taking the mean of six Cp
values (each competition assay was performed in triplicate and the
PCR was performed in duplicate). The Mean Cp values for each
competitive assay was converted into a proportion (isolate A) using
the following calculation: Proportion isolate A=1/(22DCp +1),
where DCp = Cp (isolate B) – Cp (isolate A).
Phenotype microarrays
Phenotype microarrays of osmotic/ionic response (PM 9), pH
response (PM 10) and bacterial chemical sensitivity (PM 11 to 20)
were performed as described previously by Biolog Inc. (Hayward,
California USA) [51]. BRD948 was used as a reference for
comparison with BRD948 (pHCM1) or BRD948 (pSTY7) test
isolates to identify the phenotypes affected by the presence of
IncHI1 plasmid pHCM1 (PST1) or pSTY7 (PST6).
The three isolates were pre-grown on LB (Luria-Bertani) agar
plates supplemented with 1X of an aromatic amino acid mix (a
50X aromatic amino acid mix consisted of 50 mM L-phenylala-
nine, 50 mM L-tryptophan, 1 mM para-aminobenzoic acid and
1 mM 2,3-dihydroxybenzoic acid). Sterile cotton swabs were used
to pick colonies and suspend them in 10 ml inoculating media IF-
0a (Biolog), the optical density of which was then adjusted to 0.035
absorbance units at 610 nm. A total of 750 ml of this cell
suspension was diluted 200 fold into 150 ml inoculating media IF-
10 (Biolog), containing 1X aromatic acid mix (1.2X Biolog media,
22 ml of sterile water and 3 ml of 50X aromatic amino acid mix).
PM microtitre plates 9–20 were inoculated with 100 ml of the
inoculating media cell suspension per well. Microtitre plates were
then incubated at 37uC for 48 h in the Omnilog (Biolog Inc) and
each well was monitored for colour change (kinetic respiration).
Tests were performed in duplicate and the kinetic data was
analyzed using the OmniLog PM software set (Biolog Inc). A lower
threshold of 80 omnilog units (measured as area under the kinetic
response curve) was set, and the phenotypes of each of the three
isolates were compared.
Cloning and growth curves
The fragment of two CDSs within Tn6062 of pSTY7 (3405 bp)
was amplified using two primers IS1056-03 (59-CAGGCACC-
GTTTTCTTATTAGAATCTTCGCCACT-39) and IS1056-04
(59-TCATTGAACTTTGCTACCCTGA-39). The pACYC184
fragment (2033 bp) containing its p15A ori and chloramphenicol
resistant gene (cmR) was amplified using pACYC184-01 (59-AA-
AATTACGCCCCGCCCTGC-39) and pACYC184-03 (59-TAA-
TAAGAAAACGGTGCCTGACTGCGTTAGCA-39). The two
fragments were then fused together by overlapping primer extension
PCR (pACYC184-03 and IS1056-03 were two overlapping
primers) using pACYC-01 and IS1056-04 primers. All three PCRs
above were performed using PfuUltra II Fusion HS DNA
Polymerase (Agilent, former Stratagene, UK) to achieved highly
accurate amplification. The PCRs were set up following the
manufacturer’s manual with the specific annealing temperature of
58uC and extension time of 45 s for Tn6062 and pACYC184
fragments or 1.5 min for the fusion fragment. The fused PCR
product was re-circularised by T4 ligase (New England BioLabs,
UK) to form pACYC184Dtet::Tn6062 and electroporated into
BRD948. The pACYC184 fragment was also re-circularised to
form the empty vector pACYC184Dtet and electroporated into
BRD948.
Overnight bacterial cultures of BRD948 (pHCM1), BRD948
(pSTY7), BRD948 (pACYCDtet) and BRD948 (pACYCD-
tet::Tn6062) were diluted by distilled water to the cell suspension
of 0.1 OD600 before 1 ml of the cell suspension was inoculated
into 200 ml of 0.8 M NaCl LB broth (supplemented with aro mix)
in a well of a 96-well plate. Each isolate was inoculated into six
Table 3. PCR primers for detection of resistance gene insertion sites.
Forward primer, Reverse primer Amplicon length in pAKU_1 (bp) Amplicon length in pHCM1 (bp)
G GATGGAGAAGAGGAGCAACG, TTCGTTCCTGGTCGATTTTC 989 989
H GTGCTGTGGAACACGGTCTA, TCATCAACGCTTCCTGAATG 271 1598
I ACGAAAGGGGAATGTTTCCT, CGAGTGGGAATCCATGGTAG 163 1490
J CAAAATGTTCTTTACGATGCC, CCAGACAGGAAAACGCTCA 2219 none
K CTGTGCCGAGCTAATCAACA, ACGAAAGGGGAATGTTTCCT 1314 none
L TTTTAAATGGCGGAAAATCG, GCCAGTCTTGCCAACGTTAT none 1872
M GGGCGAAGAAGTTGTCCATA, ATTCGAGCAAAACCATGGAA none 2195
N CGGGATGAAAAATGATGCTT, GGTCGGTGCCTTTATTGTTG none 2180
O GCGTACAAAAGGCAGGTTTG, GCTTGATGATGTGGCGAATA 1823 none
P TGGTCGGTGCCTTTATTGTT, GGGCGTCAGAGACTTTGTTC 1899 none
Q TTCGCCCGATATAGTGAAGG, CTAACGCCGAAGAGAACTGG 1923 none
doi:10.1371/journal.pntd.0001245.t003
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wells (i.e. six biological replicates). The bacteria were grown at
37uC with shaking at 300 rpm and OD600 was measured
automatically every 15 minutes for 24 hours in the Optima plate
reader (BMG Labtech, Germany). Absorbance data were collected
and saved in Excel format for graphing.
Results
Evolution of MDR IncHI1 plasmids
We compared the DNA sequences of eight ,200 kbp IncHI1
plasmids isolated from enteric pathogens (Table 2) and identified a
conserved IncHI1 core region (.99% identical at the nucleotide
level) that included the tra1 and tra2 regions encoding conjugal
transfer [29,33,37,52]. Subsequently, we identified 347 single
nucleotide polymorphisms (SNPs) within these conserved regions,
which were used to construct a phylogenetic tree of IncHI1
plasmids and to estimate the divergence dates of internal nodes of
this tree based on the known isolation dates for each plasmid [53]
(Figure 1). The tree topology is in general agreement with that
inferred previously using a plasmid MLST approach [37]. The
sequences of the three most recent S. Typhi plasmids (isolated
2003–2004) were very closely related and correspond to a
previously defined plasmid sequence type (PST) known as PST6
[37] (Figure 1, red). According to our divergence date estimates,
the most recent common ancestor (mrca) shared by these three
plasmids existed circa 1999 (Figure 1). The PST6 plasmids were
also closely related to the PST7 plasmid pAKU_1 from S.
Paratyphi A (Figure 1, orange), with mrca circa 1992. The
plasmids pHCM1, pO111_1 and pMAK1 formed a distinct group
corresponding to PST1, with mrca circa 1989 (Figure 1, green).
The eighth reference plasmid R27 (PST5) was quite distinct from
the others, with an estimated divergence date of 1952 (Figure 1,
black).
In addition to the conserved IncHI1 core regions, the plasmids
each harbour insertions of drug resistance elements. These include
transposons Tn10 (encoding tetracycline resistance), Tn9 (encod-
ing chloramphenicol resistance via the cat gene (SPAP0067)), strAB
(SPAP0152-SPAP0153, SPAP0230-SPAP0231; encoding strepto-
mycin resistance), sul1 and sul2 (SPAP0132 , SPAP0151; encoding
sulfonamide resistance), dfrA7 (SPAP0133; encoding trimethoprim
resistance) and blaTEM-1 (SPAP0143; encoding ampicillin resis-
tance) [29,33,54]. The insertion sites of these elements, confirmed
using PCR (Tables 3 & 4), differed between lineages of the IncHI1
phylogenetic tree (Figure 1, grey). All plasmid sequences included
Tn10, however three different insertion sites were evident
(Table 4), suggesting the transposon was acquired by IncHI1
Table 4. Resistance gene insertion sites in IncHI1 plasmids inferred from a combination of PCR and sequencing.
IncHI1 plasmid
sequence type PST1 PST5 PST6 PST6 PST7 PST8
Plasmid or isolate pHCM1 pMAK1 pO111_1 R27 p6979 pSTY7 pAKU1 81918 81863, 81424
Bacterial host STy SCh Ec STm STy STy SPa STy STy
Tn10 insertion B B B C A A A A A
sequence data B B B C A n/a A n/a n/a
N (Tn10 - HCM1.247) + n/d n/d - - - - - -
O (tetD - SPAP0276) - n/d n/d - + + + + +
P (SPAP0261 - Tn10) - n/d n/d - + + + + +
Tn9 insertion B B B - A A A - A
sequence data B B B - A n/d A n/a n/a
J (cat - trhN) - n/d n/d - + + + - +
K (mer - trhI) - n/d n/d - + + + - +
M (cat - HCM1.203) + n/d n/d - - - - - -
L (insA - tetA) + n/d n/d - - - - - -
Tn21 into Tn9 + + + - + + + - +
sequence data + + + - + n/d + n/a n/a
H (tnpA - Tn9) +* n/d n/d - + + + - +
I (merR - Tn9) +* n/d n/d - + + + - +
bla/sul/str into Tn21 + + + - + + + - +
sequence data + + + - + n/d + n/a n/a
G (strB – tniAdelta) + + + - + n/d + - +
strAB 2nd copy
(SPAP0230- SPAP0231)
- - - - - - + + +
sequence data - - - - - n/d + n/a n/a
Q (strB – SPAP0228) - n/d n/d - - - + + +
Summaries of five insertion patterns are shown in bold italics; these are inferred from sequence data where available (italics) and PCR using primers shown in Table 3
(labelled G–Q). STy = Salmonella enterica serovar Typhi, SCh = Salmonella enterica serovar Choleraesuis, STm = Salmonella enterica serovar Typhimurium, SPa =
Salmonella enterica serovar Paratyphi A, Ec = E. coli O111:H2. + positive PCR result (i.e. successful amplification); - negative PCR result (i.e. no amplification product
detected);
*distinct amplicon size for PST1; n/d PCR not done; n/a sequence data not available. ‘‘strAB 2nd’’ copy refers to the insertion of streptomycin resistance genes strAB
directly into the plasmid backbone (SPAP0230-SPAP0231), not as part of the bla/sul/str element (SPAP0152-SPAP0153).
doi:10.1371/journal.pntd.0001245.t004
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plasmids on at least three separate occasions (Figure 1, grey). Tn9
was present in all plasmids other than R27, however the insertion
site in PST6 and PST7 plasmids differed from that in PST1,
suggesting at least two independent acquisitions. It was previously
noted that pHCM1 (PST1) and pAKU_1 (PST7) share identical
insertions into Tn9 of a sequence incorporating Tn21 (including
sul1, dfrA7), blaTEM-1, sul2, and strAB [33]; here we found this
insertion into Tn9 was conserved in all PST1 and PST6 plasmid
sequences. Together, this composite set of drug resistance elements
encodes MDR (resistance to chloramphenicol, ampicillin and
trimethoprim-sulfamethoxazole).
Dissecting the emergence of MDR typhoid
In order to investigate the contribution of distinct IncHI1
plasmid types over time to the emergence of MDR S. Typhi, we
performed high resolution SNP typing of S. Typhi chromosomal
and IncHI1 plasmid loci in a global collection of 454 S. Typhi,
isolated between 1958–2007 (Table 1, Table S1). These isolates
include 19 S. Typhi isolates sequenced previously [45] and 22 S.
Typhi isolated from Kenya in 2004–2007 [22]. We also typed
eight IncHI1 S. Typhi plasmids harboured in E. coli transconju-
gants [29,37]. SNP typing was performed using the GoldenGate
(Illumina) platform to simultaneously assay chromosomal and
plasmid SNP loci. We targeted 231 SNPs from the conserved
region of the IncHI1 plasmid (Table S2, [37]; note 116 of the 347
identified SNPs were not able to be included in the GoldenGate
assay, see Methods) and 119 from resistance genes and associated
transposons (see [16]).
Of the 454 S. Typhi that we typed, 193 (43%) harboured IncHI1
plasmids, which clustered into nine distinct haplotypes (Figure 3B).
As expected, the majority of IncHI1 plasmids harboured multiple
resistance genes or elements including Tn10, Tn9, strAB, sul1, sul2,
dfrA7 and blaTEM-1. Transposon insertion sites were confirmed for
representative plasmids using PCR (Table 4) and agree with the
patterns of insertion sites determined by sequencing (Figure 1 & 3B).
Thirteen IncHI1 plasmids were identified among S. Typhi isolated
prior to 1994 (Table 5), including seven of the total nine distinct
IncHI1 plasmid haplotypes (Figure 3B).
A total of 26 distinct S. Typhi haplotypes were identified by
typing of chromosomal SNPs; their phylogenetic relationships are
shown in Figure 3A. The PST2 plasmid was detected in three S.
Typhi haplotypes isolated in Asia between 1972 and 1977
(Table 5), consistent with repeated introduction of closely related
IncHI1 plasmids into distinct S. Typhi hosts. Similarly, PST8 was
present in two S. Typhi haplotypes from Peru in 1981 (Table 5)
[55], consistent with transfer of the PST8 plasmid among multiple
S. Typhi haplotypes co-circulating in Peru at this time. Signifi-
cantly, from 1995 onwards, nearly all IncHI1 plasmids were type
PST6 (180/184 plasmids, 98%). Remarkably, there was an
exclusive relationship between PST6 plasmids and S. Typhi
haplogroup H58, with all PST6 plasmids found in S. Typhi H58
hosts, and no S. Typhi H58 harbouring non-PST6 plasmids
(although 35% of S. Typhi H58 were non-MDR and plasmid-
free). This strongly suggests that the apparent rise in MDR typhoid
since the mid-1990s [11,12,13] is due to the clonal expansion of
H58 S. Typhi carrying the MDR PST6 plasmid. This is in contrast
to the longer-term situation described above, which showed that in
the years following the first emergence of MDR typhoid (1970s–
1980s), MDR IncHI1 plasmids had transferred repeatedly into
distinct co-circulating S. Typhi haplotypes.
The clonal expansion of H58 S. Typhi has been documented
previously [22,41], however the role of the PST6 plasmid has not
been investigated. Among our collection, the oldest S. Typhi H58
isolate dates back to 1995 and carries the PST6 plasmid. To
ascertain whether the common ancestor of S. Typhi H58 might
have carried the PST6 plasmid, the phylogenetic structure among
our 293 S. Typhi H58 isolates was resolved using 45 of the assayed
SNP loci that differentiate within the H58 haplogroup (Figure 4).
Table 5. Chromosome, plasmid and resistance gene details of drug resistant S. Typhi isolated up to 1993*.
Isolate Year Country Chr Plas IS
1
ca
t
te
tA
te
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R
T
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tI
1
su
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IS
2
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B
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76–54 1976 Chile H50 7654 y y y y y y
78–851 1978 Tunisia H9 78851 y y y y y y y y
CT18 1993 Vietnam H1 PST1 y y y y y y y y y y y y y y
76–1406 1976 Indonesia H42 PST2 y y y y y y y y y
75–2507 1975 India H55 PST2 y
77–302 1977 India H55 PST2 y y y y y y y y y
77–303 1977 India H55 PST2 y y y y y y y y y
72–1907 1972 Vietnam H68 PST2 y y y y y y y y y
72–1258 1972 Mexico H11 PST3 y y y y y y y y y y
73–1102 1973 Vietnam H87 PST4 y y y y y y y y
81–863 1981 Peru H50 PST8 y y y y y y y y y y y y
81–424 1981 Peru H77 PST8 y y y y y y y y y y y y y
81–918 1981 Peru H77 PST8 y y y y y y y
57Laos 2000* Laos H1 57Laos y y y y y y y y y y y y y y
03–4747 2003* Togo H42 PST2 y y y y y y y y y y
04–6845 2004* Benin H42 PST2 y y y y y y y
Chr - S. Typhi chromosomal haplotype; Plas - IncHI1 plasmid sequence type;
*- MDR S. Typhi isolated after 1993 that were not of the H58 haplotype or PST6 IncHI1 haplotype; y - gene detected in isolate.
doi:10.1371/journal.pntd.0001245.t005
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These SNPs divided the isolates into 24 distinct H58 haplotypes,
with the majority (N=270) in 13 haplotypes (Figure 4). Most of
the H58 haplotypes (N= 14), including the ancestral haplotype A,
included isolates harbouring the PST6 plasmid (Figure 4). We
have previously sequenced the genomes of 19 S. Typhi, including
seven isolates from the H58 haplogroup [45], and observed the
insertion of an IS1 transposase between protein coding sequences
STY3618 and STY3619 within all sequenced H58 S. Typhi
genomes. This transposase was identical at the nucleotide level to
the IS1 sequences within Tn9 in IncHI1 plasmids pHCM1 and
pAKU_1, and shared a common insertion site in all seven S.
Typhi H58 chromosomes sequenced [45]. In the present study,
our SNP assays included a probe targeting sequences within the
IS1 gene (SPAP0007). Nearly all of the S. Typhi H58 isolates gave
positive signals for this IS1 target (Figure 4; coloured or white),
with the sole exception of six isolates belonging to the H58
ancestral haplotype A (Figure 4, grey), which also included three
isolates that carried the PST6 plasmid and tested positive for IS1
(Figure 4, purple). This suggests that the PST6 plasmid was likely
acquired by the most recent common ancestor of S. Typhi H58
(Figure 4, haplotype A), followed by transposition of IS1 into the S.
Typhi chromosome prior to divergence into subtypes of H58.
Thus the dominance of PST6 over other MDR IncHI1 plasmids
(noted here and previously [37]) and the dominance of H58 over
other S. Typhi haplotypes (noted here and previously [22,41])
appears to be the result of a trans-continental clonal expansion of
MDR S. Typhi H58 carrying the PST6 plasmid.
Possible selective advantages of IncHI1 PST6
These results indicate that the recent global spread of MDR
typhoid is attributable to the emergence of a single plasmid-host
combination (H58-PST6). We were able to transfer the PST6
plasmid pSTY7 from S. Typhi to E. coli [29] and back to S. Typhi
(data not shown), confirming that the PST6 plasmid retains the
Figure 4. Phylogenetic tree of the H58 haplogroup of S. Typhi. Dashed line indicates where this tree joins into the larger phylogenetic tree of
S. Typhi (shown in Figure 3A). The two major H58 lineages are indicated by colour (blue, lineage I; red, lineage II; purple, common ancestor of both
lineages). Nodes are labelled with isolate names (outer nodes representing sequenced isolates; see [45]), haplotype (H followed by number, as
defined in [41]) or letters indicating nodes resolved by SNP typing. Node sizes indicate the relative frequency of each haplotype within the study
collection of 269 H58 S. Typhi isolates, according to the scale provided. The proportion of isolates in each node carrying the PST6 plasmid and IS1
(solid colour), IS1 only (white) or neither (grey) is indicated by shading.
doi:10.1371/journal.pntd.0001245.g004
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ability to transfer between bacteria via conjugation, yet we found
no evidence of PST6 transfer in natural S. Typhi populations
(above). This raises the question of why this particular plasmid-
host association has been so successful and exclusive.
To investigate whether PST6 could confer any selective
advantage over other IncHI1 plasmids harbouring similar antimi-
crobial resistance genes, representative PST6 (pSTY7) and PST1
(pHCM1) IncHI1 plasmids from Vietnamese S. Typhi were
introduced into a common S. Typhi BRD948 host, derived from
S. Typhi Ty2 (haplotype H10). The PST1 plasmid pHCM1 was
chosen for comparison since its complete sequence is available [54]
and it was previously observed to be common in MDR S. Typhi in
Vietnam in the early 1990s, just prior to the emergence of PST6 in
S. Typhi in Vietnam and elsewhere [29]. BRD948 (pHCM1) grew
to three times the number of cfu compared to BRD948 (pSTY7)
after 4 days of mixed growth in LB broth (Figure 5, black). We
therefore hypothesized that the advantage conferred by PST6
plasmids, if any, might be related to specific environmental
conditions or to plasmid-host compatibility. To test the latter, we
compared the growth of wildtype PST1-bearing S. Typhi H1 and
PST6-bearing S. Typhi H58 isolated from typhoid patients in
Vietnam and Pakistan and genotyped using the GoldenGate assay
(listed in Table S1). The two PST6-bearing S. Typhi H58 isolates
tested were both able to out compete the PST1-bearing H1 isolate,
so that S. Typhi H1 was barely detectable after four days of
competitive growth (Figure 5, red). However plasmid-free S. Typhi
H58 isolates were also able to outcompete a plasmid-free S. Typhi
H1 isolate (Figure 5, blue), thus we cannot confirm the plasmid plays
a role in the competitive advantage of H58-PST6 S. Typhi over and
above that of the H58 chromosomal haplotype.
To screen for conditions under which PST6 plasmids confer an
advantage compared to PST1 plasmids, we used Biolog phenotyp-
ing arrays to compare the growth of plasmid-free S. Typhi
BRD948 to BRD948 (pHCM1) and BRD948 (pSTY7) under a
wide variety of conditions including various pH levels and
osmotic/ionic strengths, and a wide variety of antibiotics and
chemicals [51]. As expected, both IncHI1 plasmids conferred
enhanced growth in the presence of a wide range of antibiotics
including amoxicillin, azlocillin, oxacillin, penicillin G, pheneth-
icillin, chloramphenicol, streptomycin, gentamicin, tetracyclines
and trimethoprim (Table S3). BRD948 (pHCM1) displayed some
minor growth advantages in the presence of additional antimi-
crobials, however none of these reached clinically relevant levels
(Table S3). The only conditions under which BRD948 (pSTY7)
grew better than BRD948 and BRD948 (pHCM1) was under high
osmotic stress (3-5% NaCl or 6% KCl) (Table S3). We confirmed
this phenotype by inoculating each isolate into high salt
concentration media (0.8 M NaCl LB broth, approx. 4.7% NaCl);
only the PST6-bearing isolate BRD948 (pSTY7) was able to grow
under these conditions (Figure 6, red and grey).
We hypothesised that the osmotolerant properties of PST6
plasmids may be explained by the presence of two putative
transporters encoded within a composite transposon, Tn6062
(SPAP0100, SPAP0105, SPAP0106, SPAP0110; this transposon
was referred to as Ins1056 in [37]). Tn6062 was present in all
PST6 plasmids, the novel subtype of PST1 (57Laos) and two of the
three PST8 plasmids, but absent from all other isolates (detected
via two Tn6062-specific probes included in our SNP typing assay).
To determine if Tn6062 was responsible for the osmotolerant
phenotype of BRD948 (pSTY7), the two putative transporter
genes from Tn6062 (SPAP0105 and SPAP0106) were inserted into
the plasmid vector pAYCY184 and we assessed their effect on S.
Typhi BRD948 in high salt concentration medium (0.8 M NaCl
LB broth, approx. 4.7% NaCl). BRD948 (pAYCY184-Tn6062)
was able to grow at a slightly lower rate than BRD948 (pSTY7)
(Figure 6, blue), while BRD948 carrying the empty pAYCY184
vector was unable to grow (Figure 6, black). Therefore the
transposon Tn6062 carried by the PST6 IncHI1 plasmids confers
an osmotolerant phenotype on its S. Typhi host.
Discussion
Our analysis of IncHI1 plasmid sequences indicates that
plasmids responsible for the MDR phenotype in S. Typhi are
Figure 5. Competitive growth assays for S. Typhi H58 and H1 with and without IncHI1 plasmids. The dynamics of five competitive
growth assays conducted over four days of sequential sub-culture. Black line indicates competition in a common host background (attenuated
laboratory strain S. Typhi BRD948; haplotype H10); the proportion of PST1- and PST6-bearing bacteria at each time point was calculated by streaking
an aliquot of the sample onto agar plates and testing random colonies using a PCR that differentiates PST1 and PST6. Coloured lines indicate
competition between wildtype S. Typhi isolates as specified in the legend (see Table S1 for isolate names); the proportion of H58 and H1
chromosomes at each time point was calculated by quantifying the relative abundance of two alleles at a SNP locus that differs between H58 and H1
S. Typhi using quantitative PCR. For all assays, experiments were replicated at least three times; data points represent the mean proportion of culture
corresponding to the isolate underlined in the legend; error bars show the standard deviation of this proportion.
doi:10.1371/journal.pntd.0001245.g005
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closely related to those associated with MDR in other enteric
pathogens including S. Paratyphi A, S. Choleraesuis and
enterohaemorrhagic E. coli O111:H- (Figure 1, Table 2). These
plasmids share a recent common ancestor approximately six
decades old and have evolved into several distinct lineages via
accumulation of point mutations, followed by acquisition of
resistance elements and further point mutation (Figure 1).
Simultaneous SNP typing of plasmid and host enabled us to
differentiate between the clonal expansion of MDR S. Typhi, and
independent acquisitions of related MDR plasmids by distinct S.
Typhi hosts. Evidence for the latter includes the detection of PST2
and PST8 plasmids in co-circulating S. Typhi isolates of distinct
haplotypes in the 1970s and 1980s (Table 5). This indicates that
the emergence of MDR typhoid during this period was in part due
to transfer of IncHI1 plasmids within local S. Typhi populations.
One of the PST2-S. Typhi combinations (chromosomal haplotype
H42) was later detected among two isolates from Africa in 2003–
2004, suggesting that an individual IncHI1 plasmid may be able to
persist in a single host haplotype for decades (Table 5). In stark
contrast, all 193 PST6 plasmids were observed in S. Typhi of the
H58 haplotype and virtually all MDR S. Typhi observed after
1995 belonged to the same PST6-H58 clone, indicative of global
spread of MDR typhoid via clonal expansion. Since humans are
the only known reservoir for S. Typhi [56], it is likely that trans-
continental spread of this clone depends on international travel or
migration. If this is the case it will be particularly difficult to
control since S. Typhi can be transmitted by asymptomatic
carriers [57,58], who are usually unaware of their status and are
difficult to detect [59,60].
Our data suggest that the PST6 plasmid was acquired by the
most recent common ancestor of S. Typhi H58 (Figure 4),
implying that the expansion of S. Typhi H58 did not begin until
after acquisition of the plasmid. To our knowledge, the oldest
confirmed S. Typhi H58 isolate is 9105928K [41], which was
isolated in India in 1991 and is MDR (Mia Torpdhal, personal
communication). This suggests that the initial expansion of S.
Typhi H58 may have been associated with the acquisition of the
PST6 plasmid, implying a selective advantage over and above that
of MDR, which was also conferred by other IncHI1 plasmid types
circulating in S. Typhi in the 1990s. The only growth advantage
we detected for PST6 plasmids via our phenotype screen was that
of osmotolerance, which we showed to be conferred by the
Tn6062 transposon carried by PST6 plasmids. The transposon
Tn6062 includes betU (SPAP0106), which encodes a betaine
uptake system capable of transporting glycine betaine and proline
betaine [61]. It was first described in E. coli isolates causing
pyelonephritis (ascending urinary tract infection) and is believed to
be an osmoregulator, allowing E. coli to survive the high osmolarity
and urea content in urine [61]. However the gene is distributed
among E. coli with a range of pathogenic phenotypes, so its
osmoprotectant properties may be useful in other environmental
contexts [62]. It is possible that enhanced osmotolerance may
enhance survival of S. Typhi in specific niches within the human
body, including the gut, gall bladder, urinary tract or liver. It is
also possible that the ability to grow in the presence of high salt
concentrations might enable S. Typhi to continue replicating in
certain environments outside the host, which may lower the
infectious dose or enhance the possibility of transmission by
increasing the level of S. Typhi contamination in certain
environments. This may have contributed to the selection of
PST6 over other IncHI1 plasmids previously circulating among S.
Typhi and the initial clonal expansion of H58 S. Typhi, however
questions remain as to why the PST6 plasmid has not been
detected among non-H58 S. Typhi. The PST6 plasmid appears to
have been lost from H58 S. Typhi in some areas where the
recommended treatment of typhoid was switched to fluoroquin-
olones, including Nepal and Vietnam [39,63,64], while it has been
maintained in areas such as Kenya where chloramphenicol is still
commonly used to treat typhoid [17,22]. This confirms that
antimicrobial use exerts a strong selective pressure for mainte-
nance of the IncHI1 plasmid among S. Typhi and indicates that in
the absence of such pressure any additional advantages conferred,
Figure 6. The effect of Tn6062 on osmotolerance in S. Typhi BRD948. Growth curves for S. Typhi isolates in 0.8 M NaCl LB broth. Error bars
indicate range of maximum and minimum values.
doi:10.1371/journal.pntd.0001245.g006
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including the increased osmotolerance described above, is not
enough to maintain the PST6 plasmid indefinitely.
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